DoubleChecks

What was claimed

Immorta Bio reports 70% lifespan gain in preclinical study of aging using senolytic-regenerative therapy

Our verdict

Accurate

Immorta Bio press releases and coverage report "over 70%" or ~73% lifespan extension in validated murine aging models using a combination of SenoVax senolytic immunotherapy and personalized mesenchymal stem cells, which is a senolytic-regenerative approach. (Only 2 of 3 AI systems responded.)

All 2 AI systems agree8 sources citedChecked Jul 4, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

Immorta Bio reports 70% lifespan gain in preclinical study of aging using senolytic-regenerative therapy

Verified93%
All 2 AIs agree

Verified against 8 sources

immortabio.combioworld.comlinkedin.comimmortabio.comfirstwordpharma.comfinance.yahoo.comimmortabio.cominstagram.com

Detailed Analysis

The core claim matches Immorta Bio’s own press materials and third‑party reports. It is accurately framed as a preclinical lifespan increase in aging models using a combined senolytic and regenerative cell therapy.

Why this verdict

  • The core claim matches Immorta Bio’s own press materials and third‑party reports.
  • It is accurately framed as a preclinical lifespan increase in aging models using a combined senolytic and regenerative cell therapy.

Claims checked

Immorta Bio reports 70% lifespan gain in preclinical study of aging using senolytic-regenerative therapy

Verified93%
Immorta Bio press releases and coverage report "over 70%" or ~73% lifespan extension in validated murine aging models using a combination of SenoVax senolytic immunotherapy and personalized mesenchymal stem cells, which is a senolytic-regenerative approach.[1] [5] [6]

What other AI think

ClaudeDid not respond
Multiple sources (peer-reviewed article and company press releases) report that Immorta Bio's preclinical combination of senolytic immunotherapy (SenoVax) and regenerative stem-cell therapy produced over a 70% increase in lifespan in validated rodent aging models. The finding is presented in a published study and summarized in accompanying press materials.

Why this verdict

  • Multiple sources (peer-reviewed article and company press releases) report that Immorta Bio's preclinical combination of senolytic immunotherapy (SenoVax) and regenerative stem-cell therapy produced over a 70% increase in lifespan in validated rodent aging models.
  • The finding is presented in a published study and summarized in accompanying press materials.

Claims checked

Immorta Bio reports 70% lifespan gain in preclinical study of aging using senolytic-regenerative therapy

Verified92%
A recent peer-reviewed paper and affiliated press releases from Immorta Bio state the combination therapy produced over a 70% lifespan increase in mouse aging models.

Share this result

Try DoubleChecks